Agreed, market is unimpressed even though there is lots to like in this announcement.
Clearly there are only 2 things that will see a re-rate of this stock now:
1. Deal on Montey (partial sale/JV/full sale) - whatever will provide a clear 3rd parth pointe of reference for value and/or crystallise value
2. Actual cash flow generation (at least $10m per quarter FCF, post capex and growth), for at least a couple of quarters - this negates any noise/excues around oil price/hedging/cost overuns/production
- Forums
- ASX - By Stock
- CE1
- Ann: Montney Testing Progressing Successfully
Ann: Montney Testing Progressing Successfully, page-12
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CE1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.149M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
CE1 (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online